Author
Burrin, Douglas - Doug | |
SANGILD, PER - University Of Copenhagen | |
STOLL, BARBARA - Children'S Nutrition Research Center (CNRC) | |
THYMANN, THOMAS - University Of Copenhagen | |
BUDDINGTON, RANDAL - University Of Tennessee | |
MARINI, JUAN - Children'S Nutrition Research Center (CNRC) | |
OLUTOYE, OLUYINKA - Baylor College Of Medicine | |
SHULMAN, ROBERT - Children'S Nutrition Research Center (CNRC) |
Submitted to: Annual Review of Animal Biosciences
Publication Type: Review Article Publication Acceptance Date: 11/27/2019 Publication Date: 2/1/2020 Citation: Burrin, D.G., Sangild, P., Stoll, B., Thymann, T., Buddington, R., Marini, J., Olutoye, O., Shulman, R. 2020. Translational advances in pediatric nutrition and gastroenterology: New insights from pig models. Annual Review of Animal Biosciences. 8(321):354. https://doi.org/10.1146/annurev-animal-020518-115142. DOI: https://doi.org/10.1146/annurev-animal-020518-115142 Interpretive Summary: n/a Technical Abstract: Pigs are increasingly important animals for modeling human pediatric nutrition and gastroenterology and complementing mechanistic studies in rodents. The comparative advantages in size and physiology of the neonatal pig have led to new translational and clinically relevant models of important diseases of the gastrointestinal tract and liver in premature infants. Studies in pigs have established the essential roles of prematurity, microbial colonization, and enteral nutrition in the pathogenesis of necrotizing enterocolitis. Studies in neonatal pigs have demonstrated the intestinal trophic effects of a key gut hormone, glucagon-like peptide 2 (GLP-2), and its role in the intestinal adaptation process and efficacy in the treatment of short bowel syndrome. Further, pigs have been instrumental in elucidating the physiology of parenteral nutrition–associated liver disease and the means by which phytosterols, fibroblast growth factor 19, and a new generation of lipid emulsions may modify disease. The premature pig will continue to be a valuable model in the development of optimal infant diets (donor human milk, colostrum), specific milk bioactives (arginine, growth factors), gut microbiota modifiers (pre-, pro-, and antibiotics), pharmaceutical drugs (GLP-2 analogs, FXR agonists), and novel diagnostic tools (near-infrared spectroscopy) to prevent and treat these pediatric diseases. |